Table 6.
Treatments 1 | Item 2 | ||||||||
---|---|---|---|---|---|---|---|---|---|
ADA (U/L) | AST (U/L) | ALT (U/L) | Apo B (ng/mL) | LCAT (ng/mL) | Total Chol (ng/mL) | PLTP (ng/mL) | Free Chol (ng/mL) | G6PDH (mU/mL) | |
MT | 55.39 ± 4.12 | 159.01 ± 15.09 | 19.86 ± 4.49 | 83.02 ± 9.58 | 0.53 ± 0.02 | 11.24 ± 0.51 | 13.38 ± 2.42 | 105.18 ± 16.54 | 28.81 ± 2.74 |
MT + 0.025% YCWE | 42.75 ± 6.82 | 157.9 ± 26.08 | 18.25 ± 1.11 | 80.35 ± 28.29 | 0.62 ± 0.07 | 14.24 ± 1.43 | 16.66 ± 8.51 | 85.5 ± 28.11 | 29.21 ± 4.81 |
MT + 0.05% YCWE | 55.8 ± 8.22 | 149.13 ± 7.23 | 17.02 ± 7.93 | 142.91 ± 74.66 | 0.57 ± 0.04 | 14.05 ± 0.70 | 20.21 ± 7.59 | 26.86 ± 9.30 | 30.93 ± 1.61 |
MT + 0.1% YCWE | 59.97 ± 9.34 | 179.01 ± 11.23 | 29.25 ± 2.11 | 114.35 ± 30.67 | 0.58 ± 0.06 | 14.7 ± 1.40 | 25.89 ± 10.77 | 78.27 ± 14.49 | 28.66 ± 1.35 |
MT + 0.2% YCWE | 42.75 ± 1.44 | 180.74 ± 24.08 | 23.8 ± 4.80 | 90.91 ± 9.46 | 0.67 ± 0.06 | 12.91 ± 1.12 | 15.28 ± 3.14 | 53.13 ± 12.62 | 33.9 ± 0.73 |
MT + 0.4% YCWE | 61.91 ± 7.08 | 186.79 ± 4.40 | 33.61 ± 12.29 | 201.13 ± 33.74 | 0.62 ± 0.01 | 14.17 ± 1.18 | 31.8 ± 5.72 | 87.42 ± 25.16 | 31.05 ± 1.06 |
Treatment p-Values | |||||||||
Main effect | 0.245 | 0.550 | 0.461 | 0.256 | 0.582 | 0.321 | 0.451 | 0.122 | 0.667 |
Polynomial Contrast p-Values | |||||||||
Linear | 0.388 | 0.122 | 0.089 | 0.055 | 0.271 | 0.475 | 0.126 | 0.934 | 0.377 |
Quadratic | 0.327 | 0.551 | 0.923 | 0.446 | 0.301 | 0.551 | 0.766 | 0.085 | 0.359 |
Cubic | 0.184 | 0.842 | 0.694 | 0.237 | 0.692 | 0.051 | 0.177 | 0.350 | 0.469 |
1 MT: diet containing mycotoxins; MT + 0.025% YCWE; MT + 0.05% YCWE; MT + 0.1% YCWE; MT + 0.2% YCWE; and MT + 0.4% YCWE; 2 ADA: adenosine deaminase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; Apo B: apolipoprotein B; LCAT: lecithin cholesterol acyltransferase; Total Chol: total cholesterol; PLTP: plasma phospholipid-transfer protein; Free Chol: free cholesterol; G6PDH: glucose 6-phosphate dehydrogenase.